



SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : compliance@sudarshanpharma.com **Website :** www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) **CIN :** L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/01

Date: 3rd April 2025

To,

The Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

Sub: **Updates on acquisition of the equity shares of Ishwari Healthcare Private Limited,**
Ref: **Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

In continuation of the Company's disclosure dated 14th October 2024 (SPIL/CS/SE/2024-25/37), regarding approval of the Board to acquire 2,09,100 equity shares of Rs.10/- each of Ishwari Healthcare Private Limited (CIN 85100MH2011PTC212867), (referred to as 'Ishwari Healthcare'); pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has acquired the said 2,09,100 equity shares of Rs.10/- each of Ishwari Healthcare (51.00% of paid up equity share capital) from Mr. Shatrughan Nenwani at a revised consideration of Rs.1,50,00,000/- (Rupees One Crore And Fifty Lakhs only) i.e. at the rate of Rs.71.73/- per share.

As per the Company's previous announcement dated 14th October 2024, the consideration was fixed at Rs.2,60,00,000/- (Rupees Two Crores and Sixty Lakhs only); however, multiple rounds of negotiations, the consideration was revised at Rs.1,50,00,000/- (Rupees One Crore And Fifty Lakhs only).

Consequent to the aforesaid acquisition, Ishwari Healthcare has become a subsidiary of the Company with effect from 1st April, 2025.

This is for your information and record.

Thanks & Regards,

For, Sudarshan Pharma Industries Limited

Hemal Mehta
Chairman & Managing Director